Read the latest positive news, breakthroughs, and inspiring stories about ebola vaccine, curated daily by BrightWire.
Health workers in the Democratic Republic of Congo are receiving the first doses of a promising Ebola vaccine as part of groundbreaking clinical trials. European disease experts are also heading to the region to help contain the outbreak and protect communities.
Health workers in the Democratic Republic of Congo started receiving Ebola vaccines this weekend, offering new hope in fighting the fastest-growing outbreak in history. The rollout protects 50,000 frontline workers who risk their lives daily to care for patients.
The Democratic Republic of Congo received 70,000 doses of Ebola vaccine to combat a deadly outbreak while researchers test whether it works against this particular virus strain. The delivery marks a crucial step in protecting health workers and containing a disease that has already affected thousands.
The Democratic Republic of Congo is receiving 70,000 Ebola vaccine doses to protect frontline health workers battling the country's deadliest outbreak on record. Global health partners are stepping up to support communities facing both disease and conflict.
Scientists are racing to test whether an existing Ebola vaccine can protect people from the Bundibugyo virus outbreak in the Democratic Republic of Congo. New animal studies show the vaccine could work, offering hope as researchers prepare human trials.
Health workers are fighting to protect children in the Democratic Republic of Congo as a promising vaccine shows early signs it could help stop a deadly Ebola outbreak. After losing more than 300 young lives, a breakthrough in animal studies is opening the door to new protection.
Scientists are racing to test whether an existing Ebola vaccine could save thousands of lives in the Democratic Republic of Congo's deadliest outbreak in years. Early animal studies suggest the vaccine might work against a different strain than it was designed for.
Moderna has launched human trials for the first vaccine targeting the Bundibugyo Ebola strain devastating the Democratic Republic of Congo. Using proven mRNA technology from COVID-19, the company is racing to create protection where none currently exists.
Scientists fast-tracked a Bundibugyo Ebola vaccine from freezer to human trials in just over two months, using lessons learned from COVID-19. With 620,000 doses already manufactured, researchers aim to begin outbreak trials in Uganda by late 2026.
Scientists just gave the first human dose of a vaccine designed specifically for the Bundibugyo Ebola strain, a breakthrough that could save thousands of lives in the Democratic Republic of Congo, where over 1,000 people have already died. The vaccine went from concept to human trial in just eight weeks.
Scientists say an existing Ebola vaccine could protect people from a rapidly spreading outbreak in Congo that's killed nearly 1,000 people. New research is pushing health officials to test the vaccine now rather than wait months for new ones.
Scientists are fast-tracking three promising vaccines to fight the Ebola outbreak in Congo and Uganda, with clinical trials starting within months. New funding of $62 million is speeding up development of the first vaccines specifically designed for the Bundibugyo virus strain.
